Proactive Investors - Run By Investors For Investors
Why invest in FARN?
Faron Pharmaceuticals Ltd: DEEP DIVE

Faron Pharmaceuticals makes good start to Clevegen immunotherapy trial

Immunotherapy treatment Clevegen is on phase I/II trial (MATINS) for metastatic tumours
OVERVIEW: FARN The Big Picture
MATINS trial covers a number of cancers


  • First-in-person trial for its Clevegen cancer treatment underway

  • Two patients dosed showed increases in natural killer cells and T-Cells

  • Faron says results much better than expected

  • Indicates that Clevegen might be able to reactivate T-Cells in cancer sufferers


How is it doing

A phase III trial as a treatment for lung inflammation condition ARDS proved a major disappointment.

There was no benefit against the placebo, though Faron (LON:FARN) is working with drug regulators to work out why the results were poor and are confident Tramaukine can be of benefit to some patients.

Immunotherapy treatment Clevegen is on phase I/II trial (MATINS) for metastatic cutaneous melanoma as well as hepatobiliary/hepatocellular, pancreatic, ovarian and colorectal cancers.

Tumour cells are adept at creating a shield around themselves to evade detection by the immune system, therefore staving off destruction.

Clevegen has been designed to recognise cancer and break the cell’s protective shell.

The treatment is an anti-Clever-1 antibody which causes changes in the immune environment of solid tumours by switching Clever-1 positive immune suppressive macrophages to immune active macrophages.

Ultimately, if it is successful, this new breed of treatment will be used in combination with PD-1 inhibitors to tackle the killer disease.


What the boss says: Markku Jalkanen, CEO

Speaking about the first results of the first three people dosed in the Clevegen trial

“Previously we had believed it was impossible to reactive the T-Cells within the cancer patients so these results are quite incredible,” he said. 

“By the summer of this year, we should have a lot of questions answered,

"With a partner, we want to expand the trial in onto other cancer areas as well and as a combination therapy as well as a mono-immunotherapy."




Inflection points

More results from MATINS trial over a longer period

Faron finds a partner from the many said to be watching MATINS trial data

Traumakine reboots as a treatment for a specific type of ARDS sufferer who has a special type of genetic mutation known as C/T.


Blue Sky

If Clevegen proves to a way of re-awakening T-cells in metastatic tumours, the potential as an immunotherapy treatment is enormous

Traumakine is a smaller opportunity now but still substantial for Faron, which at 60.5p is with £19mln.

Before the Traumakine trial result, the shares almost reached 900p.

View full FARN profile View Profile

Faron Pharmaceuticals Ltd Timeline

Related Articles

February 22 2019
The company is developing drugs for blood disorders, metabolic diseases and curbing alcohol use
scientist in lab
February 25 2019
Results from a 62-patient follow-up study are due shortly, while data from a 500-person-strong managed access programme should be available by the end of next year
human kidneys
May 06 2019
The Danish company is seeking FDA approval of the test for use in both adults and children

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use